Drug Trial Radar · NCT02974725
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Last checked: Nov 19, 2026Latest source record: Apr 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
241
Actual
Start
Feb 24, 2017
Primary completion
Apr 24, 2024
Study completion Apr 24, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
Conditions
- Non-Small Cell Lung Cancer
- Melanoma
Interventions
LXH254Drug
LXH254 will be supplied as tablet for oral use.
LTT462Drug
LTT462 will be supplied as hard gelatin capsule for oral use.
TrametinibDrug
Trametinib will be supplied as film-coated tablet for oral use
RibociclibDrug
Ribociclib will be supplied in tablets and hard gelatin capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs) as a measure of safety and tolerabilityTime frame: up to 5 years
- Dose limiting toxicities (DLTs) (dose escalation only)Time frame: up to 3 years
- Tolerability measured by the number of subjects who have interruptions/reductions of study treatment and reason for interruptions/reductionsTime frame: up to 5 years
- Tolerability measured by the dose intensity of study drug, Relative Dose intensity for subjects with non-zero duration of exposure is computed as the ratio of dose intensity and planned dose intentityTime frame: Up to 5 years
Locations
32 sites in 11 countries. Site status is shown where the registry gives one.
University of California San Diego .
San Diego, California
UCSF Medical Center
San Francisco, California
Massachusetts General Hospital SC
Boston, Massachusetts
Memorial Sloan Kettering Cancer Ctr .
New York, New York
Sarah Cannon Research Institute Tennessee Oncology
Nashville, Tennessee
Uni of TX MD Anderson Cancer Cntr
Houston, Texas
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Rozzano, MI, Italy
Novartis Investigative Site
Verona, VR, Italy
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Seville, Andalusia, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Pamplona, Navarre, Spain
Novartis Investigative Site
Valencia, Valencia, Spain
Novartis Investigative Site
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.